This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

XTL Bio Signs Strategic Collaboration Framework Agreement With Clalit Research Institute And Mor Research Applications

HERZELIYA, Israel, March 15, 2012 /PRNewswire/ --

  • The agreement is expected to assist the Company with safety and efficacy data that may focus its clinical trials' design and preparations for its clinical trials and evaluation of new projects
  • Clalit Research Institute is the research arm of Clalit Health Services - Israel's largest HMO with more than 4 million members

On March 14, 2012, XTL Biopharmaceuticals announced that it entered into a strategic collaboration framework agreement with Clalit Research Institute Ltd., the research arm of Clalit Health Services ("the Institute") and Mor Research Applications, the technology transfer office of Clalit Health Services ("Mor").  

According to the agreement, upon XTL's request, the Institute will provide the Company with clinical data and analyses which would be based on the Institute's database in connection with technologies that stem from inventions and patents of Clalit Health Services' physicians. The nature of the various clinical projects shall be agreed upon by the Company, the Institute and Mor in advance.

The Company, in consideration for the above, shall pay the cost basis related to the Institute's activity in the collaboration framework of any Project plus an additional 10% of the total royalties Mor is entitled pursuant to its agreements with the Company in connection with each technology where rights were granted to the Company.

According to XTL, access to data through this agreement will enable the Company to evaluate safety and efficacy data of the technologies in development as well as technologies where development has not yet commenced.

Currently, the Company has the rights to two technologies that were in-licensed from Mor, rHuEPO for the treatment of multiple myeloma blood cancer and SAM-101 for the treatment of psychotic patients. The Company is in preparations for the implementation of its rHuEPO phase 2 clinical trial for the treatment of multiple myeloma cancer patients. In addition, the Company has the exclusive rights for SAM-101, which is based on the combination of existing anti-psychotics together with a known medicinal compound for the treatment of anti-psychotic patients with focus on schizophrenia, which has successfully completed a phase 2a in Israel.

"Our collaboration with the research institute directly supports our clinical development pipeline," said David Grossman XTL's Chief Executive Officer. "This strategic collaboration represents another important link in the ecosystem we are building around our cutting-edge technologies focused on clinical development."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs